What does a FibroMeter score of 295 with elevated α‑2‑macroglobulin indicate about the severity of liver fibrosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Understanding Your FibroMeter Result of 295 with Elevated α-2-Macroglobulin

A FibroMeter score of 295 is not a valid result—FibroMeter scores range from 0.00 to 1.00, so this value of 295 appears to be either a reporting error or represents α-2-macroglobulin measured in mg/dL rather than the actual FibroMeter score.

What This Likely Means

The number 295 most probably represents your α-2-macroglobulin level in mg/dL, which is one of the individual blood markers used to calculate FibroMeter scores, not the FibroMeter score itself 1.

Normal α-2-Macroglobulin Context

  • α-2-macroglobulin is an indirect marker of liver fibrosis that reflects liver damage and inflammation 2
  • It is one of several components used in FibroMeter calculations along with other markers like platelet count, AST, ALT, and other proteins 1
  • Elevated α-2-macroglobulin levels are associated with increased risk of liver fibrosis, particularly in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes 3

Understanding FibroMeter Scores

FibroMeter tests are specialized blood tests that provide scores between 0.00 and 1.00 to predict liver fibrosis stage 1, 4:

FibroMeter Score Interpretation Framework:

  • <0.20-0.25: Suggests minimal to no significant fibrosis (F0-F1)
  • 0.25-0.60: Intermediate range requiring further evaluation
  • >0.60-0.70: Suggests advanced fibrosis (F3-F4) 4, 5

Different FibroMeter versions exist for specific liver diseases:

  • FibroMeter Virus (V2G): For chronic viral hepatitis
  • FibroMeter NAFLD: For non-alcoholic fatty liver disease
  • FibroMeter VCTE: Combines blood markers with liver stiffness measurement 1, 6

What You Need to Do

You must obtain your actual FibroMeter score (0.00-1.00 range) from your physician to properly assess your liver fibrosis risk. The individual α-2-macroglobulin value alone cannot determine fibrosis stage 2.

Recommended Next Steps:

  1. Clarify with your physician which specific test was performed and request the complete FibroMeter score report
  2. If only α-2-macroglobulin was measured, you need the complete panel to calculate a valid FibroMeter score
  3. Consider liver stiffness measurement by transient elastography (FibroScan) combined with FibroMeter for optimal accuracy—this combination (FibroMeter VCTE) has the highest diagnostic performance with sensitivity of 83.5% and specificity of 91.1% for detecting advanced fibrosis 6

Important Clinical Context:

If you have type 2 diabetes along with fatty liver disease, elevated α-2-macroglobulin is particularly concerning as this combination significantly magnifies abnormal protein levels and fibrosis risk independently of age, sex, and obesity 3. This makes proper fibrosis assessment even more critical for your long-term prognosis.

The actual FibroMeter score, not the individual α-2-macroglobulin value, determines whether you need liver biopsy or can be monitored non-invasively 7. According to current guidelines, specialized tests like FibroMeter should be used to rule out or diagnose compensated advanced chronic liver disease (cACLD) in specialized settings 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.